• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Fresh Tracks Therapeutics Inc.

    2/14/24 1:04:27 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRTX alert in real time by email
    DEFA14A 1 a20240214defa-14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
    (Amendment No. )
    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨
    Check the appropriate box:
    o
    Preliminary Proxy Statement
    o
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o
    Definitive Proxy Statement
    x
    Definitive Additional Materials
    o
    Soliciting Material under §240.14a-12
    Fresh Tracks Therapeutics, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    x
    No fee required
    o
    Fee paid previously with preliminary materials
    o
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    On January 17, 2024, Fresh Tracks Therapeutics, Inc. (the “Company”) commenced distributing proxy materials to its stockholders, including a Notice of Special Meeting of Stockholders and Definitive Proxy Statement (the “Notice and Proxy Statement”) for its special meeting of stockholders to be held on February 15, 2024 (the “Special Meeting”). A copy of the Notice and Proxy Statement was filed with the Securities and Exchange Commission on January 17, 2024. On February 14, 2024, the Company issued a press release reminding stockholders of record to vote at the upcoming Special Meeting, which is included below.



    image_0.jpg
    Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
    Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024
    BOULDER, CO – February 14, 2024 – Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) would like to remind its stockholders to vote their proxy ahead of the Company’s upcoming special meeting of stockholders on February 15, 2024 (the “Special Meeting”) at 12:00 p.m. Eastern Time to seek stockholder approval of the liquidation and dissolution of the Company (the “Dissolution”) and the plan of liquidation and dissolution (the “Plan of Dissolution”). All stockholders of record of the Company’s outstanding shares of common stock at the close of business on January 11, 2024 may participate and vote at the Special Meeting.
    The Special Meeting on February 15, 2024 will be held via live webcast atwww.virtualshareholdermeeting.com/FRTX2024SM.
    Fresh Tracks asks that all shareholders vote their proxy now, no matter how many shares they own. Your vote is important. If you have questions about - or need assistance with - voting your proxy, please contact the Company’s proxy solicitor D.F. King at 800-769-4414 (international: 914-218-4628), or by email at [email protected].
    IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT
    This press release is for informational purposes only. It is neither a solicitation of a proxy, an offer to purchase, nor a solicitation of an offer to sell shares of the Company. In connection with the proposed Dissolution and the Plan of Dissolution, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) on January 17, 2024. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED DISSOLUTION, THE PLAN OF DISSOLUTION AND RELATED MATTERS, AND/OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT FRESH TRACKS, THE PROPOSED DISSOLUTION, THE PLAN OF DISSOLUTION AND RELATED MATTERS. Stockholders may obtain a free copy of the definitive proxy statement and the other relevant materials, and any other documents filed by the Company with the SEC, at the SEC’s website at http://www.sec.gov or on the “Investors” section of Fresh Track’s website at www.frtx.com.
    Participants in the Solicitation
    Fresh Tracks and its executive officers and directors may be deemed to be participants in the solicitation of proxies from its stockholders with respect to the proposed Dissolution, the Plan of Dissolution and related matters, and any other matters to be voted on at the Special Meeting. Information regarding the names, affiliations and direct or indirect interests, by security holdings or otherwise, of such directors and executive officers in the solicitation are included in the definitive proxy statement filed with the SEC on January 17, 2024. Additional information regarding



    such directors and executive officers, and other important Company information, are included in Fresh Track’s Annual Report on Form 10-K/A for the year ended December 31, 2022, which was filed with the SEC on May 1, 2023.
    Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Fresh Track’s stockholders in connection with the proposed Dissolution, the Plan of Dissolution and related matters are set forth in the definitive proxy statement. These documents are available free of charge as described in the preceding section.
    For more information, visit https://www.frtx.com.
    Cautionary Note Regarding Forward-Looking Statements
    Any statements made in this press release relating to future financial, business, conditions, plans, prospects, impacts, shifts, trends, progress, or strategies and other such matters, including without limitation, Fresh Tracks’ proposed Dissolution pursuant to its Plan of Dissolution, the timing of filing of the Certificate of Dissolution, the timing and outcome of the Special Meeting to approve the Dissolution and the Plan of Dissolution, the Company’s intent to seek judicial dissolution and the results of such action, the amount, number, and timing of liquidating cash distributions, if any, to its stockholders, the amount of reserves, and similar statements, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “might,” “approve,” “adjourn,” “solicit,” “continue,” “conduct,” “seek,” “distribute,” “dissolve,” “encourage,” “urge,” “discontinue,” “terminate,” “wind down,” “additional,” “announce,” “anticipate,” “believe,” “sufficient,” “estimate,” “expect,” “intend,” “plan,” “potential,” “will,” “promise,” “provide,” “unlikely,” “opportunity,” “disrupt,” “reduce,” “suggest,” “vote,” and similar expressions and their variants, as they relate to Fresh Tracks or any of Fresh Tracks’ partners, or third parties, may identify forward-looking statements. Fresh Tracks cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly, and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include the availability, timing and amount of liquidating distributions being different than expected; the amounts that will need to be set aside as reserves by Fresh Tracks being higher than anticipated; the possible inadequacy of such reserves to satisfy Fresh Tracks’ obligations; potential unknown contingencies or liabilities, and Fresh Tracks’ potential inability to favorably resolve them or at all; the amount of proceeds that might be realized from the sale or other disposition of any remaining Fresh Tracks assets; the application of, and any changes in, applicable tax and other laws, regulations, administrative practices, principles and interpretations; the incurrence by Fresh Tracks of expenses relating to the Dissolution being different than estimated; the ability of the Fresh Tracks board of directors to abandon, modify or delay implementation of the Dissolution, even after stockholder approval; failure of the Company’s stockholders to approve the proposed Plan of Dissolution; the Company’s ability to settle, make reasonable provision for or otherwise resolve its liabilities and obligations, including the establishment of an adequate contingency reserve; the timing, result, cost, and impact of any attempt to seek a judicial dissolution of the Company in case of stockholder failure to approve the Plan of Dissolution; and the uncertain macroeconomic and political environment. Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Fresh Tracks’ filings with the SEC, which are available at https://www.sec.gov (or at https://www.frtx.com). The forward-looking statements represent the estimates of Fresh Tracks as of the date hereof only. Fresh Tracks specifically disclaims any duty or obligation to update forward-looking statements.
    Fresh Tracks Therapeutics, Inc.
    Investor Contact:
    Dan Ferry
    LifeSci Advisors
    (617) 430-7576
    [email protected]

    Get the next $FRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FRTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of

      2/25/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

      BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

      6/17/24 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    SEC Filings

    See more

    $FRTX
    Financials

    Live finance-specific insights

    See more
    • SEC Form 15-12G filed by Fresh Tracks Therapeutics Inc.

      15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/18/24 5:05:32 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fresh Tracks Therapeutics Inc.

      10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/15/24 4:09:01 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/7/24 8:44:19 AM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

      5/10/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

      3/30/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

      SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      5/8/24 4:01:47 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      1/17/24 8:37:18 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      2/13/23 5:24:48 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care